Inhibition of human ovarian tumor growth by cytokine-induced killer cells.

Abstract

Despite the recent improvement in the treatment of ovarian cancer, this disease is still leading cause of cancer death in women. In this study, the anti-tumor activity of cytokine-induced killer (CIK) cells against human ovarian cancer was evaluated in vitro and in vivo. Although CD3+CD56+ cells were rare in fresh human peripheral blood mononuclear cells, they could expand more than 1,000-fold on day 14 in the presence of anti-CD3 antibody plus IL-2. At an effector-target cell ratio of 30:1, CIK cells destroyed 45% of SK-OV-3 human ovarian cancer cells, which was determined by the 51Cr-release assay. In addition, CIK cells at a dose of 23 million cells per mouse inhibited 73% of SK-OV-3 tumor growth in nude mouse xenograft assay. This study suggests that CIK cells may be used as an adoptive immunotherapy for patients with ovarian cancer.

• Authors: Hwan Mook Kim, Jong Soon Kang, Jaeseung Lim, Song-Kyu Park, Kiho Lee, Yeo Dae Yoon, Chang Woo Lee, Ki Hoon Lee, Gyoonhee Han, Kyu-Hwan Yang, Yeon Jin Kim, Youngsoo Kim, Sang-Bae Han
• Journal: Archives of pharmacal research (Arch Pharm Res) Vol. 30 Issue 11 Pg. 1464-70 (Nov 2007) ISSN: 0253-6269 [Print] Korea (South)
• PMID: 18087816 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cytokines

Topics

• Animals
• Cell Line, Tumor
• Cytokines (pharmacology)
• Female
• Humans
• Immunotherapy, Adoptive
• Killer Cells, Natural (immunology)
• Mice
• Ovarian Neoplasms (pathology, therapy)